Enzem Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 18-12-2024
- Paid Up Capital ₹ 0.50 M
as on 18-12-2024
- Company Age 10 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 M
as on 18-12-2024
- Revenue 3.80%
(FY 2022)
- Profit -18.33%
(FY 2022)
- Ebitda -7.19%
(FY 2022)
- Net Worth 8.54%
(FY 2022)
- Total Assets -9.23%
(FY 2022)
About Enzem Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹1.00 M.
Kolakunte Ramamurthy and Suma Ramamurthy serve as directors at the Company.
- CIN/LLPIN
U51101KA2014PTC075312
- Company No.
075312
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Jul 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Enzem Pharmaceuticals Private Limited offer?
Enzem Pharmaceuticals Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Multivitamin Syrup & Drops, Pain Relief Drugs & Pharmaceuticals, Diclofenac, Multivitamin Tablets & Capsules, Antioxidant Capsule, Vitamin Tablets & Capsules, Vitamin C Tablets & Capsules, Allopathic Cough Syrup, Dextromethorphan Cough Syrup.
Who are the key members and board of directors at Enzem Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kolakunte Ramamurthy  | Director | 10-Jul-2014 | Current |
| Suma Ramamurthy | Director | 20-Feb-2018 | Current |
Financial Performance of Enzem Pharmaceuticals.
Enzem Pharmaceuticals Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 3.8% increase. The company also saw a substantial fall in profitability, with a 18.33% decrease in profit. The company's net worth moved up by a moderate rise of 8.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Enzem Pharmaceuticals?
In 2022, Enzem Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 13 Feb 2020 | ₹1.00 M | Open |
How Many Employees Work at Enzem Pharmaceuticals?
Unlock and access historical data on people associated with Enzem Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Enzem Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Enzem Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
